聴letiim Bilimlerinde Arat脹rma Teknikleri (聴BAT) Dersi Bilimsel Arat脹rmalarda Etik konusu
Bu sunum, anakkale Onsekiz Mart niversitesi 聴letiim Fak端ltesi'nde verilen 聴letiim Bilimlerinde Arat脹rma Teknikleri Dersi i巽in haz脹rlanm脹t脹r.
Yrd. Do巽. Dr. Esmeray KARATA ATE
ekaratas@comu.edu.tr
May脹s 2016
Possibilities of patient education on clinical research during recruitment in...MedicReS
油
Suzanne Pozsonyi is an expert in clinical research from Hungary, specializing in patient recruitment and training for clinical trials. She highlights the importance of educating patients about clinical research, discussing various recruitment strategies that can be utilized to enhance patient involvement in trials. Effective patient recruitment practices not only empower patients but also lead to improved participation rates in clinical research.
Decision Tree for Adverse Event Reporting ALL STUDIESMedicReS
油
The document outlines a decision tree for reporting adverse events in clinical research studies, categorizing them based on their seriousness and relation to the study. It defines terms such as serious adverse event (SAE), adverse reaction (AR), and provides specific criteria for categorization in the context of clinical trials and medical devices. The decision tree applies to all studies and emphasizes the importance of clinical judgment in assessing adverse events.
MedicReS Conference 2017 Istanbul - Fostering Responsible Conduct of Research...MedicReS
油
The presentation discusses the importance of fostering responsible research conduct, highlighting historical instances of research misconduct and its definitions, including fabrication, falsification, and plagiarism. It presents survey data revealing the prevalence of unethical behavior among researchers and students, as well as notable cases of misconduct, such as that of Eric T. Poehlman, Ph.D. The document concludes with recommendations for preventing misconduct through education, compliance, and better institutional practices.
聴letiim Bilimlerinde Arat脹rma Teknikleri (聴BAT) Dersi Bilimsel Arat脹rmalarda Etik konusu
Bu sunum, anakkale Onsekiz Mart niversitesi 聴letiim Fak端ltesi'nde verilen 聴letiim Bilimlerinde Arat脹rma Teknikleri Dersi i巽in haz脹rlanm脹t脹r.
Yrd. Do巽. Dr. Esmeray KARATA ATE
ekaratas@comu.edu.tr
May脹s 2016
Possibilities of patient education on clinical research during recruitment in...MedicReS
油
Suzanne Pozsonyi is an expert in clinical research from Hungary, specializing in patient recruitment and training for clinical trials. She highlights the importance of educating patients about clinical research, discussing various recruitment strategies that can be utilized to enhance patient involvement in trials. Effective patient recruitment practices not only empower patients but also lead to improved participation rates in clinical research.
Decision Tree for Adverse Event Reporting ALL STUDIESMedicReS
油
The document outlines a decision tree for reporting adverse events in clinical research studies, categorizing them based on their seriousness and relation to the study. It defines terms such as serious adverse event (SAE), adverse reaction (AR), and provides specific criteria for categorization in the context of clinical trials and medical devices. The decision tree applies to all studies and emphasizes the importance of clinical judgment in assessing adverse events.
MedicReS Conference 2017 Istanbul - Fostering Responsible Conduct of Research...MedicReS
油
The presentation discusses the importance of fostering responsible research conduct, highlighting historical instances of research misconduct and its definitions, including fabrication, falsification, and plagiarism. It presents survey data revealing the prevalence of unethical behavior among researchers and students, as well as notable cases of misconduct, such as that of Eric T. Poehlman, Ph.D. The document concludes with recommendations for preventing misconduct through education, compliance, and better institutional practices.
MedicReS Conference 2017 Istanbul - Journal Metrics: The Impact Factor and Al...MedicReS
油
The document discusses the use of journal impact factors (IF) as a metric for journal selection among authors and readers, highlighting its calculation and significance in the publishing industry. It outlines the advantages and problems associated with using IF, including potential biases and research misconduct, while also suggesting alternatives like article-level metrics. The summary concludes that while IF is a useful measure, it should not be the sole criterion for evaluating a journal or individual research outputs.
MedicReS Conference 2017 Istanbul - Ethical issues of secondary analysis of a...MedicReS
油
The document discusses the ethical issues surrounding the secondary analysis of archived healthcare data, particularly electronic health records (EHR) and genetic data. Key concerns include privacy, informed consent, data management, and potential harms from genetic testing. Additionally, it addresses relevant U.S. legislation and the importance of ethical practices in the use of genetic information and biobanking.
MedicReS Conference 2017 Istanbul - Integrity of Authorship in Research Publi...MedicReS
油
The document discusses issues of authorship integrity and plagiarism in research publications, highlighting various international cases of plagiarism and the resulting consequences for authors in different countries. It emphasizes the need for clear guidelines on authorship, including participation requirements and accountability, to prevent misconduct and promote ethical practices in academic publishing. The recommendations aim to clarify authors' contributions and responsibilities, thereby reducing confusion and protecting against false accusations of misconduct.
MedicReS Winter School 2017 Vienna - Ethics of Cancer Trials - Adil E. ShamooMedicReS
油
The document discusses the ethical considerations and historical context of cancer research involving human subjects, focusing on various clinical trial phases and the unique challenges associated with phase I trials in cancer patients. It outlines key ethical guidelines, such as informed consent and the principles from the Nuremberg Code and Belmont Report, emphasizing the need for transparency about risks and benefits in clinical trials. The presentation aims to provide a comprehensive understanding of how to ethically conduct cancer research while considering patient welfare and scientific integrity.
MedicReS Winter School 2017 Vienna - Importance of Selection of Outcomes - Ma...MedicReS
油
This document discusses the importance of selecting appropriate outcomes and covariates when conducting comparative effectiveness research using observational data. It notes that outcomes should be clinically relevant and meaningful to patients, while covariates should be pre-treatment variables that are associated with both the exposure and outcome in order to control for confounding. The document provides an example of a study evaluating chemotherapy toxicity in older breast cancer patients that selected hospitalization as the outcome and adjusted for several patient characteristics in its analysis to account for potential biases in observational data.
MedicReS Winter School 2017 Vienna - Advanced Clinical Practice in Oncology -...MedicReS
油
The document discusses statistical methodologies utilized in cancer research, particularly focusing on the analysis of outcomes using logistic regression and Cox proportional hazards models. It highlights the disparities in cervical cancer mortality rates between racial groups and emphasizes accurate population assessments in epidemiological studies. Additionally, it provides insights into various modeling techniques for examining the relationships between exposures and health outcomes in cancer studies.
MedicReS Winter School 2017 Vienna - Advanced Clinical Practice in Oncology -...MedicReS
油
The document discusses comparative effectiveness research (CER), contrasting randomized controlled trials (RCTs) and observational studies regarding cancer treatment and patient outcomes. It emphasizes the differences between efficacy and effectiveness, outlining various study designs such as pragmatic trials, cluster-randomized trials, and cohort studies, while addressing common biases like confounding and lead time bias. Additionally, it presents examples and methodological considerations for evaluating interventions and the complexities involved in data collection and interpretation within diverse patient populations.
FDA 2013 Clinical Investigator Training Course: The Investigator as the Custo...MedicReS
油
The document outlines the responsibilities of an investigator in managing clinical trial data, emphasizing adherence to protocols, good clinical practices (GCP), and the importance of accurate and timely reporting. It highlights the need for effective site management, patient safety, data integrity, and protocol adherence to ensure the safety and efficacy of medications. Early identification and correction of issues are critical for maintaining data quality and protecting patient welfare.
FDA 2013 Clinical Investigator Training Course: The Investigator: A Trusted P...MedicReS
油
The document outlines the essential steps and considerations for successful site operations in clinical research, emphasizing the role of human resources, facility management, and compliance. It presents survey data on site activation, feasibility assessment, and enrollment performance across various investigative sites. The findings highlight discrepancies between perception and reality regarding time commitment and resource allocation in study processes.
FDA 2013 Clinical Investigator Training Course: The Investigator as Collabora...MedicReS
油
The document discusses the essential role of clinical investigators in advancing medical research and patient care through clinical trials. It emphasizes the importance of community outreach, education, and advocacy to improve trial efficiency and knowledge transfer to practice. Additionally, it highlights the responsibility of investigators to communicate results and contribute to the adoption of medical innovations derived from trial findings.
FDA 2013 Clinical Investigator Training Course: The Physician as Clinician an...MedicReS
油
The document emphasizes the essential role of physicians as both clinicians and investigators in conducting quality clinical trials, highlighting the importance of thorough testing, proper protocol design, and accountability for patient safety. Physicians must responsibly enroll eligible subjects, ensure informed consent, and maintain vigilance with adverse events while collaborating with sponsors. Ultimately, participation in clinical trials is positioned as a valuable and safe experience that enriches medical practice.
FDA 2013 Clinical Investigator Training Course: A Patient Advocates Perspect...MedicReS
油
The document presents a personal account from Jane Reese-Coulbourne, highlighting the importance of clinical trials in cancer research and patient care. It discusses both the positive and negative aspects of participating in trials, including patient autonomy and concerns about efficacy, while emphasizing the need for better patient navigation and trust in the system. The document also underscores the vital role of patient advocates in the drug development process, improving trial design and patient involvement.
FDA 2013 Clinical Investigator Training Course: Serious Drug Induced Liver In...MedicReS
油
The document outlines the significance of Drug-Induced Liver Injury (DILI) and its potential severity, which can lead to serious health risks and regulatory implications for drug approval. It details the liver's functions, the risks associated with various drugs, and how to assess the likelihood and severity of liver damage due to medications. Additionally, the document emphasizes the importance of identifying susceptible patients and implementing guidelines for monitoring liver function during clinical trials and post-marketing evaluations.
FDA 2013 Clinical Investigator Training Course: Special Cardiac Safety Concerns MedicReS
油
The document discusses the detection of drug-related cardiac safety signals in clinical trials, focusing on QT prolongation and its implications in drug development. It presents several case studies, including the risks associated with antiarrhythmic drugs and notable withdrawals like fenfluramine and rofecoxib, highlighting the complexities and challenges in monitoring cardiovascular safety. The talk emphasizes the need for improved strategies to identify and evaluate proarrhythmic risks in pharmaceutical development.
FDA 2013 Clinical Investigator Training Course: Special Cardiac Safety Concerns MedicReS
油
Ad
MedicReS BeGMR TITCK IKU Tanimlar
1. Advers Olay
Klinik arat脹rmaya itirak eden
g旦n端ll端de g旦r端len ve uygulanan
tedavi ile nedensellik ilikisi olsun
veya olmas脹n ortaya 巽脹kan istenmeyen
t端m t脹bbi olaylard脹r. Arat脹rma
端r端n端yle ilgili kabul edilsin veya
edilmesin, ge巽ici olarak arat脹rma
端r端n端n端n kullan脹m脹 ile ilgili anormal
bir laboratuvar bulgusu d但hil her t端rl端
sak脹ncal脹 ve istenmeyen bulgu,
semptom veya hastal脹k advers olay
olarak nitelendirilebilir.
TANIMLAR
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
2. Advers Reaksiyon
Klinik arat脹rmaya itirak eden g旦n端ll端de ortaya
巽脹kan istenmeyen ve ama巽lanmayan t端m
cevaplard脹r. Yeni bir t脹bbi 端r端n veya t脹bbi 端r端n端n
yeni kullan脹mlar脹na ilikin ruhsatland脹rma 旦ncesi
klinik arat脹rmalarda, 旦zellikle tedavi ama巽l脹 dozlar
hen端z belirlenmemi olabileceinden, t脹bbi
端r端n端n bu durumu da d但hil olmak 端zere herhangi
bir dozuyla mant脹kl脹 bir nedensel ilikiye sahip
olarak deerlendirilen b端t端n advers olaylar advers
reaksiyon olarak tan脹mlan脹r. Mant脹kl脹 nedensel iliki
ifadesi, nedensel bir iliki 旦ne s端rmek i巽in bir kan脹t
veya bir g旦r端 olduunu ifade etmek i巽in kullan脹l脹r.
Ruhsatl脹 端r端nler i巽in advers reaksiyon insanlarda
hastal脹klar脹n profilaksisi, tehisi, tedavisi veya bir
fizyolojik fonksiyonun deitirilmesi i巽in kullan脹lan
normal dozdaki bir ilaca verilen sak脹ncal脹 ve
istenmeyen etki anlam脹na gelmektedir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
4. Arat脹rma Bro端r端
Arat脹r脹lan 端r端nle veya
uygulamayla ilgili klinik
olmayan ve klinik verilere ait
belgelerdir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
5. Arat脹rma Protokol端
Klinik arat脹rman脹n amac脹n脹,
tasar脹m脹n脹, metodolojisini,
uygulanacak istatistiksel
y旦ntemleri ve arat脹rmaya
ait d端zenlemeleri detayl脹
olarak tan脹mlayan belgedir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
6. Arat脹rma Protokol端 Deiiklii
Arat脹rma protokol端 端zerinde
yap脹lan deiikliklere ilikin
belgedir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
7. Arat脹rma r端n端
Klinik arat脹rmada test
edilen veya referans olarak
kullan脹lan aktif maddenin
veya plasebonun farmas旦tik
formudur.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
8. Ba脹ms脹z Veri 聴zleme Komitesi
(Veri 聴zleme Grubu veya Veri G端venlilik
聴zleme Komitesi)
Klinik arat脹rman脹n ilerlemesini, g端venlilik
verilerini ve gerekirse kritik etkililik sonlan脹m
noktalar脹n脹 deerlendiren ve destekleyiciye
arat脹rman脹n devam etmesi, deitirilmesi
veya durdurulmas脹 y旦n端nde belirli aral脹klarla
旦neride bulunmak 端zere arat脹rma d脹脹ndaki
ba脹ms脹z uzmanlar脹n oluturduu bir
komitedir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
9. Beklenmeyen Advers
Reaksiyon
Nitelii, iddeti veya sonucu
referans g端venlilik bilgileri
ile tutarl脹 olmayan her t端rl端
ciddi advers reaksiyondur.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
10. Bilgilendirilmi G旦n端ll端 Olur
Formu (BGOF):
Arat脹rma hakk脹nda ayr脹nt脹l脹
ve anla脹l脹r bilgiler verilerek
al脹nan r脹zay脹 yaz脹l脹 ekilde
ispatlayan belgedir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
11. Bilgisayar Destekli Sistemlerin
Dorulanmas脹
Bilgisayar destekli bir sistemin belirli
gereksinimlerinin s端rekli yerine
getirilebildiini ortaya koyan ve
belgelendiren bir
s端re巽tir. Dorulama ilemi sistemin
tasar脹m脹ndan servisten 巽脹kar脹lmas脹na
veya yeni bir sisteme ge巽ie kadar
doruluu, g端venilirlii ve s端rekli
hedeflenen performans脹 salamal脹d脹r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
12. Biyoedeerlik
Farmas旦tik edeer olan iki
m端stahzar脹n, ayn脹 molar dozda
veriliinden sonra
biyoyararlan脹mlar脹n脹n ve b旦ylece
etkilerinin hem etkililik, hem
g端venlik bak脹m脹ndan esas olarak
ayn脹 olmas脹n脹 salayacak
derecede benzer olmas脹d脹r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
13. Biyoyararlan脹m
Etkin maddenin veya onun
terap旦tik molek端l k脹sm脹n脹n
farmas旦tik ekilden absorbe
edilerek sistemik dola脹ma
ge巽me ve b旦ylece v端cuttaki etki
yerinde veya onu yans脹tan
biyolojik s脹v脹larda genellikle
serum veya plazmada var olma
h脹z脹 ve derecesidir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
14. Ciddi Advers Olay veya
Reaksiyon
l端me, hayati tehlikeye,
hastaneye yatmaya veya
hastanede kalma s端resinin
uzamas脹na, kal脹c脹 veya 旦nemli bir
sakatl脹a ya da maluliyete,
doumsal anomaliye veya
kusura neden olan advers olay
ya da reaksiyondur.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
15. ift-Sa脹r Maskeleme
(Double Dummy)
Bir arat脹rma 端r端n端n端n iki farkl脹
farmas旦tik eklinin kar脹lat脹r脹laca脹
arat脹rmalarda, arat脹rma gruplar脹na
hangi 端r端nlerin verildiinin
maskelenmesi i巽in kullan脹lan bir
k旦rleme y旦ntemidir. Buna g旦re
旦rnein, bir gruba plasebo tablet ve
aktif madde i巽eren ampul, dier gruba
ise aktif madde i巽eren tablet ve
plasebo ampul verilmek suretiyle
arat脹rma gruplar脹na uygulama yap脹l脹r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
16. ok Merkezli Klinik Arat脹rma
Tek bir protokole g旦re
birden fazla merkezde
y端r端t端len, bu sebeple
birden fazla sorumlu
arat脹rmac脹n脹n bulunduu
klinik arat脹rmad脹r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
17. Denetim
Klinik arat脹rma yap脹lan yerlerin,
destekleyici veya s旦zlemeli arat脹rma
kuruluuna ait merkezlerin,
arat脹rmaya ait belgeler ve kay脹tlar脹n,
kalite g端vencesi d端zenlemelerinin ve
arat脹rma ile ilgili olan etik kurullar
d但hil dier kurum, kurul ve
kurulular脹n ilgili mevzuata uygunluu
a巽脹s脹ndan 旦nceden haber vererek
veya haber vermeden Kurum
taraf脹ndan incelenmesi faaliyetidir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
18. Denetim Raporu
聴lgili sal脹k otoritesi
taraf脹ndan denetim
sonucunda haz脹rlanan
rapordur.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
20. Dorudan Eriim
Klinik arat脹rman脹n deerlendirilmesi
amac脹yla arat脹rmaya ait kay脹t ve raporlar脹
inceleme, analiz etme, dorulama ve
kopyalama iznidir. 皆温鉛脹一 Bakanl脹脹 ve bal脹
kurulular脹, T端rkiye 聴la巽 ve T脹bbi Cihaz
Kurumu, ilgili sal脹k otoriteleri ve yoklama
yapan kiiler gibi dorudan eriimi bulunan
b端t端n taraflar, g旦n端ll端lerin kimlikleri veya
destekleyicinin m端lkiyetindeki bilgilerin
gizliliini korumak amac脹yla, ilgili mevzuatla
getirilen s脹n脹rlamalar 巽er巽evesinde gerekli
旦nlemleri almal脹d脹rlar.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
21. Dok端mantasyon
Klinik arat脹rmaya ait y旦ntem,
uygulama veya arat脹rman脹n
sonu巽lar脹n脹, arat脹rmay脹
etkileyen fakt旦rleri ve
ger巽ekletirilen eylemleri
a巽脹klayan veya kaydeden yaz脹l脹,
elektronik ve manyetik kay脹t,
tarama kayd脹, r旦ntgen ve
elektrokardiyogram kayd脹 gibi
her t端rl端 belgedir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
22. Etik Kurul
G旦n端ll端lerin haklar脹, g端venlii ve
esenliinin korunmas脹 amac脹yla
arat脹rma ile ilgili dier konular脹n yan脹
s脹ra g旦n端ll端lerin bilgilendirilmesinde
kullan脹lacak y旦ntem ve belgeler ile bu
kiilerden al脹nacak olurlar hakk脹nda
bilimsel ve etik y旦nden g旦r端 vermek
端zere tekil edilecek ve T端rkiye 聴la巽 ve
T脹bbi Cihaz Kurumunca onaylanacak
ba脹ms脹z kurullard脹r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
23. Etkilenebilir zneler
Klinik arat脹rmaya g旦n端ll端 olma istei kabul edilsin
veya edilmesin kat脹l脹m脹n脹n salayaca脹 yarar
beklentisi veya kat脹lmay脹 reddettii takdirde
hiyerarik yap脹 i巽inde bulunan kiiler taraf脹ndan
misilleme g旦recei beklentisi nedeniyle 旦zg端r
karar verme iradesi etkilenebilecek kiilerdir. T脹p,
eczac脹l脹k, di hekimlii ve hemirelik 旦rencileri,
arat脹rma yap脹lan yere bal脹 巽al脹an hastane veya
laboratuvar personeli, ila巽 sekt旦r端nde 巽al脹anlar,
silahl脹 kuvvetler mensuplar脹, er ve erbalar ile
tutuklular gibi belirli bir hiyerarik yap脹 i巽erisinde
bulunan kiiler bunlara 旦rnektir. Ayr脹ca, tedavi
edilemeyen bir hastal脹脹 olan hastalar, bak脹m
evlerinde yaayanlar, isiz veya yoksul kiiler, acil
t脹bbi m端dahale gereken kiiler, 巽ocuklar, onay
verme ehliyeti bulunmayanlar ve bunun gibi kiiler
de bu hassas gruba d但hildir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
24. Gerekli Temel Belgeler
Arat脹rman脹n
ger巽ekletirilme ekli ve elde
edilen verilerin kalitesinin
deerlendirilmesine bireysel
ve toplu olarak olanak veren
temel belgelerdir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
26. G旦n端ll端
Bizzat kendisinin veya
kanuni temsilcisinin yaz脹l脹
oluru al脹nmak suretiyle
klinik arat脹rmaya itirak
edecek hasta veya sal脹kl脹
kiilerdir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
27. G旦n端ll端 Kodu
Arat脹rmaya kat脹lan g旦n端ll端lerin
kimliinin gizli kalmas脹 amac脹yla
sorumlu arat脹rmac脹 veya dier
arat脹rmac脹lar taraf脹ndan her bir
g旦n端ll端ye verilen ve herhangi bir
advers olay veya arat脹rmayla
ilgili veriler rapor edilirken
g旦n端ll端n端n ad脹 yerine kullan脹lan
koddur.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
28. 聴dar樽 Sorumlu
ok merkezli bir arat脹rmada,
gerektiinde arat脹rman脹n
y端r端t端lmesi s脹ras脹nda arat脹rma ile
ilgili idar樽 konularda bu merkezlerin
sorumlu arat脹rmac脹lar脹 ile etik kurul,
destekleyici veya destekleyicinin yasal
temsilcisi ve gerekirse bunlar ile
Kurum aras脹ndaki koordinasyondan
sorumlu olan tercihen uzmanl脹k veya
doktora eitimini tamamlam脹 kiidir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
29. 聴yi Klinik Uygulamalar脹 (聴KU)
Arat脹rmalar脹n uluslararas脹 bilimsel ve etik
standartlarda yap脹lmas脹n脹 salamak amac脹yla
arat脹rman脹n tasarlanmas脹, y端r端t端lmesi,
izlenmesi, b端t巽elendirilmesi,
deerlendirilmesi ve raporlanmas脹,
g旦n端ll端n端n t端m haklar脹n脹n ve v端cut
b端t端nl端端n端n korunmas脹, arat脹rma
verilerinin g端venilirliinin salanmas脹,
gizliliinin muhafaza edilmesi gibi konular
hakk脹ndaki d端zenlemeleri kapsayan ve
arat脹rmaya itirak eden taraflarca uyulmas脹
gereken kurallard脹r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
30. 聴zin
(T端rkiye 聴la巽 ve T脹bbi Cihaz
Kurumu 聴zni)
聴yi klinik uygulamalar脹 ve ilgili
mevzuata g旦re belirlenen
s脹n脹rlar d但hilinde arat脹rman脹n
ilgili merkezlerde
ger巽ekletirilebileceine dair
T端rkiye 聴la巽 ve T脹bbi Cihaz
Kurumunun olumlu karar脹d脹r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
31. 聴zleme
Klinik arat脹rmada kaydedilen
ilerlemenin izlenmesi ve klinik
arat脹rman脹n arat脹rma
protokol端, standart 巽al脹ma
y旦ntemleri (SY), iyi klinik
uygulamalar脹 ve ilgili mevzuata
uygun olarak ger巽eklemesinin
salanmas脹d脹r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
32. 聴zleme Raporu
Yap脹lan her merkez ziyareti
sonras脹 veya arat脹rmayla ilgili
taraflarla iletiimden sonra
destekleyicinin standart 巽al脹ma
y旦ntemini temel alarak
haz脹rlanan ve izleyici taraf脹ndan
destekleyiciye sunulan yaz脹l脹
rapordur.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
33. Kalite G端vencesi
Arat脹rman脹n iyi klinik
uygulamalar脹 ve ilgili mevzuata
uygun olarak
ger巽ekletirilmesini, verilerin
buna uygun olarak
oluturulmas脹n脹, belgelenmesini,
kaydedilmesini ve
raporlanmas脹n脹 g端venceye
almak amac脹yla planlanm脹
sistematik eylemlerin t端m端d端r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
34. Kalite Kontrol
Arat脹rmayla ilgili faaliyetlerin
kalite koullar脹n脹n yerine
getirildiini dorulamak
amac脹yla, kalite g端vence sistemi
i巽erisinde kullan脹lan operasyonel
teknikler ve ger巽ekletirilen
faaliyetlerdir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
35. Kanun樽 Temsilci
Y端r端rl端kte olan mevzuat
uyar脹nca, potansiyel g旦n端ll端
ad脹na, g旦n端ll端n端n klinik
arat脹rmaya kat脹l脹m脹
konusunda onay vermeye
yetkili k脹l脹nan kiidir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
36. Kar脹lat脹rma r端n端
Klinik arat脹rmada referans
olarak kullan脹lan 端r端n veya
plasebodur.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
37. Kaynak Belgeler
Hastane kay脹tlar脹, laboratuvar notlar脹,
bilgi notlar脹, g旦n端ll端lerin g端nl端kleri
veya deerlendirme kontrol listeleri,
ila巽 da脹t脹m kay脹tlar脹, otomatik
ara巽lardan elde edilen kay脹tl脹 veriler,
bunlar脹n doru ve eksiksiz olduu
doruland脹ktan sonra onaylanan
kopyalar脹, fotoraf negatifleri,
mikrofilm, r旦ntgen filmleri ve
arat脹rmaya kat脹lan laboratuvar ve
mediko-teknik b旦l端mlerde tutulan
kay脹tlar gibi kay脹tlar orijinal
belgelerdir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
38. Kaynak Veriler
Klinik arat脹rmaya ait bulgular脹n
ve g旦zlemlerin, klinik
arat脹rmayla ilgili dier
faaliyetlere ait ve orijinal
kay脹tlarda veya orijinal kay脹tlar脹n
onayl脹 suretlerinde bulunan
bilgilerin t端m端d端r. Kaynak
veriler kaynak belgelerde
tutulur.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
39. Klinik Arat脹rma
Bir veya birden fazla arat脹rma
端r端n端n端n klinik, farmakolojik veya
dier farmakodinamik etkilerini ortaya
巽脹karmak ya da dorulamak, advers
olay veya reaksiyonlar脹n脹 tan脹mlamak,
emilim, da脹l脹m, metabolizma ve
at脹l脹m脹n脹 tespit etmek, g端venliliini ve
etkililiini arat脹rmak amac脹yla
insanlar 端zerinde y端r端t端len
巽al脹malard脹r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
40. Klinik Arat脹rma Ara Raporu
Arat脹rman脹n ara sonu巽lar脹
ve arat脹rma s端resince
ger巽ekletirilen analizlere
dayanarak yap脹lan
deerlendirmelere ilikin
rapordur.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
41. Klinik Arat脹rma Raporu
Herhangi bir terap旦tik,
profilaktik veya tan脹sal ama巽la
ilgili olarak g旦n端ll端lerde
y端r端t端len bir arat脹rman脹n klinik
ve istatistiksel tan脹m, sunum ve
analizlerini t端m端yle tek bir rapor
i巽inde b端t端nletirmek suretiyle
yap脹lan yaz脹l脹 bir tan脹mlamad脹r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
42. Klinik Olmayan al脹ma
聴nsan g旦n端ll端ler 端zerinde
yap脹lmayan biyomedikal
巽al脹malard脹r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
43. Koordinat旦r
ok merkezli bir arat脹rmada bu
merkezlerin sorumlu arat脹rmac脹lar脹
ile etik kurul, destekleyici veya
destekleyicinin yasal temsilcisi ve
gerekirse T端rkiye 聴la巽 ve T脹bbi Cihaz
Kurumu aras脹ndaki koordinasyonun
salanmas脹ndan sorumlu uzmanl脹脹n脹
veya doktoras脹n脹 tamamlam脹 hekim
veya di hekimidir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
44. K旦rleme (Maskeleme)
Arat脹rma s脹ras脹nda g旦n端ll端ye hangi arat脹rma
端r端n端n端n uyguland脹脹n脹n arat脹rmada yer
alan sorumlu arat脹rmac脹 veya dier
arat脹rmac脹, g旦n端ll端 veya izleyici gibi bir veya
birden 巽ok taraf taraf脹ndan bilinmemesine
denir. Tek k旦rleme genellikle g旦n端ll端n端n
bilgilendirilmemesini, 巽ift k旦rleme ise
genellikle g旦n端ll端, sorumlu arat脹rmac脹 veya
dier arat脹rmac脹, izleyici ve baz脹 durumlarda
veri analistlerinin verilen tedavi hakk脹nda
bilgilendirilmemesini ifade etmektedir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
45. Merkez Organizasyon Y旦netimi
Hizmeti
Arat脹rma dosyalar脹n脹n d端zenlenmesi,
g旦n端ll端lerin vizitelere haz脹rlanmas脹
gibi arat脹rma prosed端rlerinin
y端r端t端lmesi ilerinin yerine
getirilmesi i巽in sorumlu arat脹rmac脹
talebi dorultusunda destekleyiciden
ba脹ms脹z olarak arat脹rma
merkezlerine s旦zlemeli arat脹rma
kuruluu taraf脹ndan verilen hizmetler
b端t端n端d端r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
46. Olgu Rapor Formu (ORF)
Arat脹rmadaki her bir
g旦n端ll端ye ait verilerin ve
dier bilgilerin arat脹rma
protokol端nde tan脹mland脹脹
ekilde kayd脹n脹n yap脹lmas脹
i巽in haz脹rlanan bas脹l脹, optik
veya elektronik belgedir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
47. Onay (Etik Kurul Onay脹)
聴yi klinik uygulamalar脹 ve
ilgili mevzuata g旦re
belirlenen s脹n脹rlar d但hilinde,
arat脹rman脹n ilgili
merkezlerde
ger巽ekletirilebileceine dair
etik kurulun olumlu
karar脹d脹r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
48. Primer (Birincil)
Sonlan脹m Noktas脹
Birincil veri salayan
arat脹rmadaki en 旦nemli
sonlan脹m noktas脹d脹r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
49. Randomizasyon
(Rastgele Yerletirme)
Yanl脹l脹脹 azaltmak amac脹yla,
g旦n端ll端lerin tedavi veya
kontrol gruplar脹na
da脹t脹lmas脹n脹n ansa g旦re
yap脹lmas脹 ilemidir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
50. Saha G旦revlisi
Arat脹rma dosyalar脹n脹n d端zenlenmesi,
g旦n端ll端lerin vizitelere haz脹rlanmas脹
gibi arat脹rma prosed端rlerinin
y端r端t端lmesi ilerinin yerine
getirilmesi i巽in arat脹rma merkezinde
sorumlu arat脹rmac脹 talebi
dorultusunda destekleyiciden
ba脹ms脹z olarak g旦revlendirilmi
nitelikli kiilerdir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
51. Sekonder (聴kincil) Sonlan脹m
Noktas脹
Arat脹rmadaki primer
sonlan脹m noktas脹ndan daha
az 旦nemli olan sonlan脹m
noktas脹d脹r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
52. Sonlan脹m Noktas脹
Arat脹rman脹n temel ilgi
alanlar脹ndan biri olan deiken
olarak tan脹mlanabilir. Bu
deiken etkililik ve g端venlilik ile
ilgili olabilir. Sonlan脹m noktas脹
etkililik deikenlii ve g端venlilik
deikenlii ile ayn脹 anlamlarda
kullan脹labilir, ancak demografik
deikenlikle ayn脹 anlamda
kullan脹lmaz.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
53. Sorumlu Arat脹rmac脹
Arat脹rma konusu ile ilgili
uzmanl脹k dal脹nda eitimini
tamamlam脹 ve arat脹rman脹n
y端r端t端lmesinden sorumlu
olan hekim veya di
hekimidir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
54. S旦zleme
Yap脹lacak ilerin devredilmesine,
da脹t脹m脹na, gereinde mali
konulara ilikin d端zenlemeleri
belirleyen ve iki veya daha fazla
ilgili taraf aras脹nda yap脹lan yaz脹l脹,
tarihli, imzal脹 anlamad脹r.
Arat脹rma protokol端, s旦zlemeye
temel oluturabilir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
55. S旦zlemeli Arat脹rma Kuruluu
(SAK)
Destekleyicinin klinik arat脹rma
ile ilgili g旦rev ve yetkilerinin
t端m端n端 veya bir k脹sm脹n脹 yaz脹l脹
bir s旦zlemeyle devrettii, iyi
klinik uygulamalar脹 ilkelerine
uygun 巽al脹an ba脹ms脹z
kurulutur.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
56. Standart al脹ma Y旦ntemleri
(SY)
聴yi klinik uygulamalar脹
ilkelerine ve ilgili
tamamlay脹c脹 rehberlik ve
destek salamak amac脹yla
oluturulmu olan ayr脹nt脹l脹
yaz脹l脹 talimatlard脹r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
57. Tarafs脹z Tan脹k
G旦n端ll端 veya kanuni temsilcisinin
okuma bilmemesi gibi durumlarda
g旦n端ll端n端n bilgilendirilmesiyle ilgili
s端re巽te bilgilendirilmi g旦n端ll端 olur
formu ve dier yaz脹l脹 bilgileri
g旦n端ll端ye okuyan, arat脹rma ekibinde
yer almayan, arat脹rmayla ilgisi
olmayan ve arat脹rmada yer alan
kiiler taraf脹ndan etki alt脹nda
b脹rak脹lmamas脹 gereken kiidir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
58. Uyun巽
Arat脹rmayla ilgili b端t端n
koullara, iyi klinik
uygulamalar脹na ve ilgili
mevzuata uyulmas脹d脹r.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
59. Yard脹mc脹 Arat脹rmac脹
Sorumlu arat脹rmac脹n脹n g旦zetimi ve
denetimi alt脹nda arat脹rma yerinde
巽al脹mak 端zere, arat脹rmayla ilgili
kritik y旦ntemlerin uygulanmas脹 veya
arat脹rmayla ilgili 旦nemli kararlar脹n
al脹nmas脹 hususlar脹nda sorumlu
arat脹rmac脹 taraf脹ndan g旦revlendirilen
arat脹rma ekibinin 端yesidir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
60. Yoklama
Arat脹rmayla ilgili faaliyetler ile
arat脹rmadan elde edilen verilere ait
kay脹t, analiz ve doru raporlama
ilemlerinin arat脹rma protokol端,
destekleyicinin standart 巽al脹ma
y旦ntemleri, iyi klinik uygulamalar脹 ve
ilgili mevzuata uygun olarak
ger巽ekletirilip ger巽ekletirilmedii
hususlar脹n脹 arat脹rmak amac脹yla,
arat脹rmayla ilgili faaliyetlerin ve
dok端man脹n ba脹ms脹z ve sistematik
olarak incelenmesidir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
61. Yoklama 聴zi
Olaylar脹n ak脹脹n脹 g旦steren
dok端mantasyondur.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr
63. Yoklama Raporu
Yoklamay脹 yapan kii
taraf脹ndan, yoklaman脹n
sonu巽lar脹yla ilgili olarak
haz脹rlanan yaz脹l脹
deerlendirmedir.
This presentation has been prepared by using TITCK IKU GUIDANCE www.titck.gov.tr